Endurant Stent Graft System, Endurant II Stent Graft System, Endurant IIs Stent Graft System
Medtronic Vascular · Decision date Sep 15, 2025
What did the FDA approve?
FDA records P100021/S129 as a supplement to PMA P100021, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 15, 2025.
FDA approval order statement
Approval to remove a warning from the device labeling regarding lack of safety and effectiveness data on the use of your device in emergency treatment of aneurysms, as well as a brief summary of the supportive data with regard to treatment of ruptured aneurysms.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 15, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P100021/S129
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular
- Product code
- MIH
- Decision code
- APPR
- Decision date
- Sep 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- Medtronic Vascular
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100021/S129 received
Application receipt date recorded by FDA.
P100021/S129 · FDA decision
Real-Time Process
P100021/S131 · Related supplement
Endurant II/IIs Stent Graft System
P100021/S133 · Related supplement
Endurant Stent Graft System; Endurant II/IIs Stent Graft System; Endurant II AUI Stent Graft System
P100021/S134 · Related supplement
Endurant, Endurant II/lls Stent Graft System
P100021/S132 · Related supplement
Endurant II/IIs Stent Graft System
Timeline entries are records held by MedtechLedger for P100021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Endurant II/IIs Stent Graft SystemP100021/S131 | Medtronic Vascular | PMA supplement | Oct 23, 2025 | FDA |
| Medtronic Vascular | PMA supplement | Jan 27, 2026 | FDA | |
Endurant, Endurant II/lls Stent Graft SystemP100021/S134 | Medtronic Vascular | PMA supplement | Feb 27, 2026 | FDA |
Endurant II/IIs Stent Graft SystemP100021/S132 | Medtronic Vascular | PMA supplement | May 12, 2026 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P100021/S129
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




